secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0000950170-25-045231
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta cuts workforce 34%, CFO departs; NKX019 autoimmune data due H2 2025; cash into 2029
--------------------------------------------------------------------------------

- Workforce reduction of 34% (53 positions) to cut costs and extend cash runway into 2029.
- CFO Alyssa Levin terminates March 31; President Nadir Mahmood named principal financial officer.
- Cash $380.5M as of Dec 31, 2024; expects cash to fund operations into 2029.
- Net loss FY2024 $108.8M ($1.60/share), Q4 $25.9M ($0.35/share).
- Preliminary NKX019 clinical data from Ntrust-1 and Ntrust-2 trials expected H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017025045231/0000950170-25-045231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017025045231/nktx-20250326.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-045231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer